RAN and cancer: Apart from TARBP2 and RAN, our trial sequential analysis results showed that the cumulative evidence for miRNA gene machinery variants was inadequate, and additional primary allelic discrimination studies for the other nine genes are warranted to validate the outcomes in various types of cancers.